Biotek-snakken — Marts 2021
-
STRO-002 + Keytruda + Cytokine derivative ville godt nok være en drømmekombination! Jeg kan ikke huske om jeg tidligere har postet, men i Mercks Q4 presentation er Sutro angivet som en af Mercks vigtige oncology partners på slide 18 (for øvrigt sammen med Moderna, Eisai, Seagen og AstraZeneca, så fint selskab
) -
-
Derudover markedsfører Merck jo også Lynparza i ovarian cancer sammen med AstraZeneca, det er måske endnu en kombinationsmulighed
-
Jazz, indlæg længere om insiderkøb for 1,5 mill. Kunne ligne en trendvending...langt om længe, den har godt fået bank i lang tid....sikkert pga emission til en meget lav kurs omkring 18-19....den var dyr for kursen, men nu ligner det en vending.
-
Er der nogen der har et bud på hvorfor cantargia er nede med 8% idag?
-
Saniona fra Red Eye.... https://www.redeye.se/research/807432/saniona-what-a-signal-value?
utm_medium=email&utm_source=note -
A total of eleven board members and management executives invested for a total of SEK 1.5 million. The invested amount is secondary this time, though. It is the signal value that encourages us. For many of them, this was their first direct investment in Saniona. We want to highlight that the insider purchases took place on the open market and were not part of an incentive program. Hence, each transaction is to be seen as separate and personal investments.
-
@fandel se under Bava/ZP
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind